BioCentury
ARTICLE | Clinical News

IMP321: Interim Ph IIb AIPAC data

January 13, 2017 8:29 PM UTC

Interim data from 15 patients with hormone receptor-positive metastatic breast cancer in the open-label portion of the European Phase IIb AIPAC trial showed that 6 and 30 mg doses of subcutaneous IMP3...